Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jul 21, 2022 10:26am
197 Views
Post# 34840186

RE:RE:RE:Beyond the BCG-unresponsive market

RE:RE:RE:Beyond the BCG-unresponsive market

Hi Infinity....
I don't know a lot about this particular local irradiation treatment, but from what I can gather it is reported to be prostate-specific via its binding to PSMA (prostate-specific membrane antigen....a transmembrane protein found in prostate cancer cells).  However, as you implied, PSMA is found in other types of cancer cell tissues, including bladder cancer/NMIBC as demonstrated in prior studies.  However, it isn't clear to me if the amount/intensity of PSMA expression is high enough in bladder cancer/NMIBC for this type of treatment to be effective.  That is, the clinical utility of PSMA may be confined to the above form of prostate cancer.  Additionally, PSMA is also expressed in healthy bladder tissue (though at a different level), & there would likely be risk to healthy bladder tissue while the drug is being cleared from your body post treatment....in other words, drink plenty of water for a few days.

So, this form of treatment does not come without its systemic/radiation-exposure side effects (including bone marrow suppression)...it is given systemically/IV in multiple doses (I believe 6 doses).  And per Pluvicto's safety precautions, once you've been treated, you must also take radiation-exposure precautions.  There are recommended human/household contact limitations ranging from 2 to 15 days depending on individual circumstances.

Pluvicto's use for our indication would obviously require years of additional study/clinical trialing, & considering its mechanism of action, side effects & requisite precautions, I don't see this being serious competition anytime soon, if ever (especially if being considered as a single-agent option).  All imo.  Good luck...

<< Previous
Bullboard Posts
Next >>